4. Barbacid M. (1993) Nerve growth factor: a tale of two receptors. Oncogene 8, 2033–2042.
5. Beck K. D., Irwin I., Valverde J., Brennan T. J., Langston J. W. and Hefti F. (1996) GDNF induces a dystonia-like state in neonatal rats and stimulates
dopamine and serotonin synthesis. Neuron 16, 665–673.
6. Beck K. D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R. A., Rosenthal A. and Hefti F. (1995) Mesencephalic dopaminergic neurons
protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373, 339–341.
7. Blochl A. and Sirrenberg C. (1996) Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75Lntr receptors.
J. biol. Chem. 271, 21100–21107.
8. Bowenkamp K. E., Hoffman A. F., Gerhardt G. A., Henry M. A., Biddle P. T., Hoffer B. J. and Granholm A. C. (1995) Glial cell line-derived neurotrophic
factor supports survival of injured midbrain dopaminergic neurons. J. comp. Neurol. 355, 479–489.
9. Buj-Bello A., Adu J., Pinon L. G., Horton A., Thompson J., Rosenthal A., Chinchetru M., Buchman V. L. and Davies A. M. (1997) Neurturin
responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase. Nature 387, 721–724.
10. Cass W. A. (1996) GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J. Neurosci.
16, 8132–8139.
11. Chao M. V. (1992) Neurotrophin receptors: a window into neuronal differentiation. Neuron 9, 583–593.
12. Choi-Lundberg D. L., Lin Q., Chang Y.-N., Chiang Y. L., Hay C. M., Morrison P. F., Dedrick R. L. and Bohn M. C. (1997) Dopaminergic neurons
protected from degeneration by GDNF gene therapy. Science 275, 838–841.
13. Crews C., Alessandrini A. and Erikson E. (1992) The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258,
478–480.
14. Dudley D. T., Pang L., Decker S. J., Bridges A. J. and Saltiel A. R. (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc.
natn. Acad. Sci. U.S.A. 92, 7686–7689.
15. Durbec P., Marcos G. C., Kilkenny C., Grigoriou M., Wartiowaara K., Suvanto P., Smith D., Ponder B., Costantini F., Saarma M., Sariola H. and Pachnis
V. (1996) GDNF signalling through the Ret receptor tyrosine kinase. Nature 381, 789–793.
16. Finkbeiner S., Tavazoie S. F., Maloratsky A., Jacobs K. M., Harris K. M. and Greenberg M. E. (1997) CREB: a major mediator of neuronal neurotrophin
responses. Neuron 19, 1031–1047.
17. Galpern W. R., Frim D. M., Tatter S. B., Altar C. A., Beal M. F. and Isacson O. (1996) Cell-mediated delivery of brain-derived neurotrophic factor
enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant. 5, 225–232.
18. Gao W., Dugich-Djordjevic M. M., Weil R. J. and Lu B. (1997) Therapeutical usage of neurotrophic factors: patent analysis. Expert Opin. Ther. Patents
7, 325–338.
19. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F., Hoffer B. J. and Gerhardt G. A.
(1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252–255.
20. Grammer T. C. and Blenis J. (1997) Evidence for MEK-independent pathways regulating the prolonged activation of the ERK–MAP kinases. Oncogene
14, 1635–1642.
21. Gunn-Moore F. J., Williams A. G., Toms N. J. and Tavare J. M. (1997) Activation of mitogen-activated protein kinase and p70S6 kinase is not correlated
with cerebellar granule cell survival. Biochem. J. 324, 365–369.
22. Hefti F. (1997) Pharmacology of neurotrophic factors. A. Rev. Pharmac. Toxic. 37, 239–267.
23. Herbert M. A., Horne C. G. V., Hoffer B. J. and Gerhardt G. A. (1996) Functional effects of GDNF in normal rat striatum: presynaptic studies using in
vivo electrochemistry and microdialysis. J. Pharmac. exp. Ther. 279, 1181–1190.
24. Hoffer B. J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L. F. and Gerhardt G. A. (1994) Glial cell line-derived neurotrophic factor
reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182, 107–111.
25. Hudson J., Granholm A. C., Gerhardt G. A., Henry M. A., Hoffman A., Biddle P., Leela N. S., Mackerlova L., Lile J. D., Collins F., et al. (1995) Glial cell
line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36, 425–432.
26. Hyman C., Hofer M., Barde Y. A., Juhasz M., Yancopoulos G. D., Squinto S. P. and Lindsay R. M. (1991) BDNF is a neurotrophic factor for
dopaminergic neurons of the substantia nigra. Nature 350, 230–232.
27. Ip N. and Yancopoulos G. D. (1996) The neurotrophins and CNTF: two families of collaborative neurotrophic factors. A. Rev. Neurosci. 19, 491–515.
28. Jing S., Wen D., Yu Y., Holst P. L., Luo Y., Fang M., Tamir R., Antonio L., Hu Z., Cupples R., Louis J. C., Hu S., Altrock B. W. and Fox G. M. (1996)
GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85, 1113–1124.
29. Jing S., Yu Y., Fang M., Hu Z., Holst P. L., Boone T., Delaney J., Schultz H., Zhou R. and Fox G. M. (1997) GFRalpha-2 and GFRalpha-3 are two new
receptors for ligands of the GDNF family. J. biol. Chem. 272, 33111–33117.
30. Kearns C. M. and Gash D. M. (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672, 104–111.
31. Klein R. D., Sherman D., Ho W. H., Stone D., Bennett G. L., Moffat B., Vandlen R., Simmons L., Gu Q., Hongo J. A., Devaux B., Poulsen K., Armanini
M., Nozaki C., Asai N., Goddard A., Phillips H., Henderson C. E., Takahashi M. and Rosenthal A. (1997) A GPI-linked protein that interacts with Ret to
form a candidate neurturin receptor. Nature 387, 717–721.
32. Knusel B., Winslow J. W., Rosenthal A., Burton L. E., Seid D. P., Nikolics K. and Hefti F. (1991) Promotion of central cholinergic and dopaminergic
neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc. natn. Acad. Sci. U.S.A. 88, 961–965.
33. Kotzbauer P. T., Lampe P. A., Heuckeroth R. O., Golden J. P., Creedon D. J. Jr, Johnson E. M.Jr and Milbrandt J. (1996) Neurturin, a relative of glial-cellline-derived neurotrophic factor. Nature 384, 467–470.
34. Lapchak P. A., Jiao S., Miller P. J., Williams L. R., Cummins V., Inouye G., Matheson C. R. and Yan Q. (1996) Pharmacological characterization of glial
cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell Tiss. Res.
286, 179–189.
35. Levivier M., Przedborski S., Bencsics C. and Kang U. J. (1995) Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived
neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 15, 7810–7820.
36. Lewin G. R. and Barde Y.-A. (1996) Physiology of the neurotrophins. A. Rev. Neurosci. 19, 289–317.
37. Lin L. F., Doherty D. H., Lile J. D., Bektesh S. and Collins F. (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic
neurons. Science 260, 1130–1132.
38. Lin L. F., Zhang T. J., Collins F. and Armes L. G. (1994) Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor.
J. Neurochem. 63, 758–768.
39. Lindsay R. M., Altar C. A., Cedarbaum J. M., Hyman C. and Wiegand S. J. (1993) The therapeutic potential of neurotrophic factors in the treatment of
Parkinson's disease. Expl Neurol. 124, 103–118.
40. Marsh H. N. and Palfrey H. C. (1996) Neurotrophin-3 and brain-derived neurotrophic factor activate multiple signal transduction events but are not
survival factors for hippocampal pyramidal neurons. J. Neurochem. 67, 952–963.
41. Marsh H. N., Scholz W. K., Lamballe F., Klein R., Nanduri V., Barbacid M. and Palfrey H. C. (1993) Signal transduction events mediated by the BDNF
receptor gp 145trkB in primary hippocampal pyramidal cell culture. J. Neurosci. 13, 4281–4292.
42. Marshall C. J. (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80,
179–185.
43. Martin I. M. and Altar C. A. (1996) Spontaneous behaviours of rats are differentially affected by substantia nigra infusions of brain-derived neurotrophic
factor and neurotrophin-3. Eur. J. Neurosci. 8, 1696–1706.
44. Milbrandt J., de Sauvage F. J., Fahrner T. J., Baloh R. H., Leitner M. L., Tansey M. G., Lampe P. A., Heuckeroth R. O., Kotzbauer P. T., Simburger K. S.,
